PRODUCTS & SERVICES
MultiplexDX's CEO, Dr. Pavol Cekan, recently spoke on RTVS about the retrospective clinical validation of a novel cancer diagnostic method. This is a major breakthrough in cancer detection and could potentially save countless lives. Our team used a combination of innovative technologies to develop a highly accurate diagnostic method that is able to detect and reclassify multiple types of cancer.
The retrospective clinical validation showed promising results and the method is now ready for further validation and implementation. This is a significant milestone for MultiplexDX and for the field of cancer research as a whole. Our team has worked tirelessly to develop this innovative approach to cancer diagnosis, and their hard work is paying off.
We look forward to seeing how this method will continue to be validated and implemented in the fight against cancer.
To see the full interview, click here.
MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).
MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.